Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Biosimilars and Bioanalytical Methods, and Rheumatoid Arthritis Research and Therapies.
Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
Alimentary Pharmacology & Therapeutics2024cited by 30position: middledoi
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
Therapeutic Advances in Gastroenterology2022cited by 37position: firstdoi